Skip to main content
Erschienen in: memo - Magazine of European Medical Oncology 3/2018

13.04.2018 | short review

Hemoglobinopathies—genetically diverse, clinically complex, and globally relevant

verfasst von: Prof. Dr. Holger Cario

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 3/2018

Einloggen, um Zugang zu erhalten

Summary

Hemoglobinopathies represent the most frequent monogenic disorders worldwide. Migration during recent years led to a profoundly increasing number of patients in countries where the indigenous population has not been affected. This short review will give an overview on etiology, pathogenesis, clinical features, diagnostics, and treatment of the most relevant hemoglobinopathies, i.e., the thalassemias and sickle cell disease.
Literatur
1.
Zurück zum Zitat Kohne E. Hemoglobinopathies: clinical manifestations, diagnosis, and treatment. Dtsch Arztebl Int. 2011;108(31–32):532–40.PubMedPubMedCentral Kohne E. Hemoglobinopathies: clinical manifestations, diagnosis, and treatment. Dtsch Arztebl Int. 2011;108(31–32):532–40.PubMedPubMedCentral
3.
Zurück zum Zitat Patrinos GP, Giardine B, Riemer C, Miller W, Chui DH, Anagnou NP, et al. Improvements in the HbVar database of human hemoglobin variants and thalassemia mutations for population and sequence variation studies. Nucleic Acids Res. 2004;32:D537–D41.CrossRefPubMedPubMedCentral Patrinos GP, Giardine B, Riemer C, Miller W, Chui DH, Anagnou NP, et al. Improvements in the HbVar database of human hemoglobin variants and thalassemia mutations for population and sequence variation studies. Nucleic Acids Res. 2004;32:D537–D41.CrossRefPubMedPubMedCentral
5.
7.
Zurück zum Zitat Cario H, Grosse R, Janssen G, Jarisch A, Meerpohl J, Strauss G. Guidelines for diagnostics and treatment of secondary iron overload in patients with congenital anemia. Klin Padiatr. 2010;222(6):399–406.CrossRefPubMed Cario H, Grosse R, Janssen G, Jarisch A, Meerpohl J, Strauss G. Guidelines for diagnostics and treatment of secondary iron overload in patients with congenital anemia. Klin Padiatr. 2010;222(6):399–406.CrossRefPubMed
9.
Zurück zum Zitat Premawardhena A, Arambepola M, Katugaha N, Weatherall DJ. Is the beta thalassaemia trait of clinical importance? Br J Haematol. 2008;141(3):407–10.PubMed Premawardhena A, Arambepola M, Katugaha N, Weatherall DJ. Is the beta thalassaemia trait of clinical importance? Br J Haematol. 2008;141(3):407–10.PubMed
10.
Zurück zum Zitat Taher AT, Musallam KM, Cappellini MD, Weatherall DJ. Optimal management of beta thalassaemia intermedia. Br J Haematol. 2011;152(5):512–23.CrossRefPubMed Taher AT, Musallam KM, Cappellini MD, Weatherall DJ. Optimal management of beta thalassaemia intermedia. Br J Haematol. 2011;152(5):512–23.CrossRefPubMed
11.
Zurück zum Zitat Taher A, Vichinsky E, Musallam KM, Cappellini MD, Viprakasit V, editors. Guidelines for the management of non transfusion dependent thalassemia. Nicosia: Thalassemia International Federation; 2013. Taher A, Vichinsky E, Musallam KM, Cappellini MD, Viprakasit V, editors. Guidelines for the management of non transfusion dependent thalassemia. Nicosia: Thalassemia International Federation; 2013.
12.
Zurück zum Zitat Algiraigri AH, Kassam A. Hydroxyurea for hemoglobin E/beta-thalassemia: a systematic review and meta-analysis. Int J Hematol. 2017;106(6):748–56.CrossRefPubMed Algiraigri AH, Kassam A. Hydroxyurea for hemoglobin E/beta-thalassemia: a systematic review and meta-analysis. Int J Hematol. 2017;106(6):748–56.CrossRefPubMed
13.
Zurück zum Zitat Cario H, Wegener M, Debatin KM, Kohne E. Treatment with hydroxyurea in thalassemia intermedia with paravertebral pseudotumors of extramedullary hematopoiesis. Ann Hematol. 2002;81(8):478–82.CrossRefPubMed Cario H, Wegener M, Debatin KM, Kohne E. Treatment with hydroxyurea in thalassemia intermedia with paravertebral pseudotumors of extramedullary hematopoiesis. Ann Hematol. 2002;81(8):478–82.CrossRefPubMed
14.
Zurück zum Zitat Musallam KM, Taher AT, Cappellini MD, Sankaran VG. Clinical experience with fetal hemoglobin induction therapy in patients with beta-thalassemia. Blood. 2013;121(12):2199–212.CrossRefPubMed Musallam KM, Taher AT, Cappellini MD, Sankaran VG. Clinical experience with fetal hemoglobin induction therapy in patients with beta-thalassemia. Blood. 2013;121(12):2199–212.CrossRefPubMed
15.
Zurück zum Zitat Motta I, Scaramellini N, Cappellini MD. Investigational drugs in phase I and phase II clinical trials for thalassemia. Expert Opin Investig Drugs. 2017;26(7):793–802.CrossRefPubMed Motta I, Scaramellini N, Cappellini MD. Investigational drugs in phase I and phase II clinical trials for thalassemia. Expert Opin Investig Drugs. 2017;26(7):793–802.CrossRefPubMed
16.
Zurück zum Zitat Cappellini MD, Cohen A, Porter J, Taher A, Viprakasit V, editors. Guidelines for the Management of Transfusion Dependent Thalassaemia (TDT). Nicosia: Thalassemia International Federation; 2014. Cappellini MD, Cohen A, Porter J, Taher A, Viprakasit V, editors. Guidelines for the Management of Transfusion Dependent Thalassaemia (TDT). Nicosia: Thalassemia International Federation; 2014.
17.
Zurück zum Zitat King A, Shenoy S. Evidence-based focused review of the status of hematopoietic stem cell transplantation as treatment of sickle cell disease and thalassemia. Blood. 2014;123(20):3089–94.CrossRefPubMed King A, Shenoy S. Evidence-based focused review of the status of hematopoietic stem cell transplantation as treatment of sickle cell disease and thalassemia. Blood. 2014;123(20):3089–94.CrossRefPubMed
18.
Zurück zum Zitat Negre O, Eggimann AV, Beuzard Y, Ribeil JA, Bourget P, Borwornpinyo S, et al. Gene Therapy of the beta-Hemoglobinopathies by Lentiviral Transfer of the beta(A(T87Q))-Globin Gene. Hum Gene Ther. 2016;27(2):148–65.CrossRefPubMedPubMedCentral Negre O, Eggimann AV, Beuzard Y, Ribeil JA, Bourget P, Borwornpinyo S, et al. Gene Therapy of the beta-Hemoglobinopathies by Lentiviral Transfer of the beta(A(T87Q))-Globin Gene. Hum Gene Ther. 2016;27(2):148–65.CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Piel FB, Steinberg MH, Rees DC. Sickle cell disease. N Engl J Med. 2017;376(16):1561–73.CrossRefPubMed Piel FB, Steinberg MH, Rees DC. Sickle cell disease. N Engl J Med. 2017;376(16):1561–73.CrossRefPubMed
20.
Zurück zum Zitat Zhang D, Xu C, Manwani D, Frenette PS. Neutrophils, platelets, and inflammatory pathways at the nexus of sickle cell disease pathophysiology. Blood. 2016;127(7):801–9.CrossRefPubMedPubMedCentral Zhang D, Xu C, Manwani D, Frenette PS. Neutrophils, platelets, and inflammatory pathways at the nexus of sickle cell disease pathophysiology. Blood. 2016;127(7):801–9.CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Ware RE, de Montalembert M, Tshilolo L, Abboud MR. Sickle cell disease. Lancet. 2017;390(10091):311–23.CrossRefPubMed Ware RE, de Montalembert M, Tshilolo L, Abboud MR. Sickle cell disease. Lancet. 2017;390(10091):311–23.CrossRefPubMed
22.
Zurück zum Zitat Hankins JS, Ware RE, Rogers ZR, Wynn LW, Lane PA, Scott JP, et al. Long-term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension study. Blood. 2005;106(7):2269–75.CrossRefPubMedPubMedCentral Hankins JS, Ware RE, Rogers ZR, Wynn LW, Lane PA, Scott JP, et al. Long-term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension study. Blood. 2005;106(7):2269–75.CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Voskaridou E, Christoulas D, Bilalis A, Plata E, Varvagiannis K, Stamatopoulos G, et al. The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS). Blood. 2010;115(12):2354–63.CrossRefPubMed Voskaridou E, Christoulas D, Bilalis A, Plata E, Varvagiannis K, Stamatopoulos G, et al. The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS). Blood. 2010;115(12):2354–63.CrossRefPubMed
24.
Zurück zum Zitat DeBaun MR, Kirkham FJ. Central nervous system complications and management in sickle cell disease. Blood. 2016;127(7):829–38.CrossRefPubMed DeBaun MR, Kirkham FJ. Central nervous system complications and management in sickle cell disease. Blood. 2016;127(7):829–38.CrossRefPubMed
25.
Zurück zum Zitat Metcalf B, Chuang C, Dufu K, Patel MP, Silva-Garcia A, Johnson C, et al. Discovery of GBT440, an orally bioavailable R‑state stabilizer of sickle cell hemoglobin. ACS Med Chem Lett. 2017;8(3):321–6.CrossRefPubMedPubMedCentral Metcalf B, Chuang C, Dufu K, Patel MP, Silva-Garcia A, Johnson C, et al. Discovery of GBT440, an orally bioavailable R‑state stabilizer of sickle cell hemoglobin. ACS Med Chem Lett. 2017;8(3):321–6.CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat Ataga KI, Kutlar A, Kanter J, Liles D, Cancado R, Friedrisch J, et al. Crizanlizumab for the prevention of pain crises in sickle cell disease. N Engl J Med. 2017;376(5):429–39.CrossRefPubMed Ataga KI, Kutlar A, Kanter J, Liles D, Cancado R, Friedrisch J, et al. Crizanlizumab for the prevention of pain crises in sickle cell disease. N Engl J Med. 2017;376(5):429–39.CrossRefPubMed
Metadaten
Titel
Hemoglobinopathies—genetically diverse, clinically complex, and globally relevant
verfasst von
Prof. Dr. Holger Cario
Publikationsdatum
13.04.2018
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 3/2018
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-018-0402-4

Weitere Artikel der Ausgabe 3/2018

memo - Magazine of European Medical Oncology 3/2018 Zur Ausgabe